Local News: Yala, Thailand 

 | 

Sign Up

 | 

Sign In

Watson Pharmaceuticals News Editors

News Widget

Display the Watson Pharmaceuticals news headlines on your website.

Get the Topix Headlines Widget

Share & bookmark

RSS icon mobile icon

Watson Pharmaceuticals News

News on Watson Pharmaceuticals (Ticker: WPI) continually updated from thousands of sources around the net.

6 hrs ago | Drug Store News

Watson confirms Beyaz patent challenge

A subsidiary of Watson Pharmaceuticals is seeking approval for its version of an oral contraceptive from the Food and Drug Administration.

Comment?

Related Topix: Biotech, Medicine, Pharmaceuticals, Healthcare Industry, Food and Drug Administration, Manufacturing, Bayer HealthCare, Chemicals

15 hrs ago | Freshnews

Columbia Laboratories Transfers NDA for Progesterone Vaginal Gel 8% to Watson Pharmaceuticals

LIVINGSTON, N.J. and PARSIPPANY, N.J., Feb.13, 2012 /PRNewswire/ -- Columbia Laboratories, Inc.

Comment?

Related Topix: Biotech, Medicine, Pharmaceuticals, Healthcare Industry, Columbia Laboratories, Columbian Chemicals, Chemicals, Livingston, NJ, Healthcare Law, Law, Food and Drug Administration

15 hrs ago | Seeking Alpha

Watson Pharmaceuticals (WPI) seeks FDA approval to market generic...

Watson Pharmaceuticals seeks FDA approval to market generic Beyaz after facing a lawsuit from Bayer challenging a patent on the drug.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Pharmaceuticals

Fri Feb 10, 2012

The Washington Post

Bayer Sues Watson Over Patent for Beyaz Birth Control Pill

A unit of Bayer AG, Germany's largest drugmaker, sued Watson Pharmaceuticals Inc., accusing the generic-drug maker of violating a patent for Beyaz birth control pills.

Comment?

Related Topix: Biotech, Medicine, Pharmaceuticals, Healthcare Industry, Wilmington, DE, World News, Germany, Business News

Benzinga

Watson Confirms Beyaz Patent Challenge

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Drospirenone and Ethinyl Estradiol and Levomefolate Calcium Tablets, 3.0 mg/0.02 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Pharmaceuticals, Food and Drug Administration

Thu Feb 09, 2012

Forbes.com

Forbes Earnings Preview: Watson Pharmaceuticals

Leading up to Watson Pharmaceuticals ' announcement of its fourth quarter earnings on Tuesday, February 14, 2012, analysts have become more bullish as expectations have improved over the past month from $1.61 per share to the current projection of earnings of $1.75 per share.

Comment?

Related Topix: Biotech, Medicine, Pharmaceuticals, Healthcare Industry, Financial Markets

Wall St. Cheat Sheet

Watson Pharmaceuticals Inc. Fourth Quarter Earnings Sneak Peek

S&P 500 component Watson Pharmaceuticals, Inc. will unveil its latest earnings on Tuesday, February 14, 2012.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Pharmaceuticals

GlobeSt.com

Watson Comes to North Brunswick

Join the thousands of real estate professionals that subscribe to the New Jersey AM Alert.

Comment?

Related Topix: New Jersey, North Brunswick, NJ, Biotech, Medicine, Pharmaceuticals, Healthcare Industry, Chris Christie, US Governors, Rutgers University, Parsippany, NJ

Bloomberg

Watson CEO Seeks Deal in Brand-Name Drugs

Watson Pharmaceuticals Inc. Chief Executive Officer Paul Bisaro is looking to acquire brand-name drug assets and make a future "'transformational'' purchase as he reshapes the generic-drug maker.

Comment?

Related Topix: Biotech, Medicine, Pharmaceuticals, Healthcare Industry, Sales, Teva Pharmaceutical Industries, Ims Health, Computers, Advertising

Wed Feb 08, 2012

Wall St. Cheat Sheet

Stock Analyst Alerts: Rambus, Hartford Financial, Freeport-McMoRan,...

Rambus Inc. : BWS Financial believes Rambus' settlement with NVIDA is a significant positive surprise since it brings an end to a costly legal battle for the company.

Comment?

Related Topix: Startups, NVidia, Rambus, Hartford Financial Services Group, Insurance, Real Estate, Freeport, Biotech, Medicine, Pharmaceuticals, Healthcare Industry

CBS News

Watson and J&J settle Ortho Tri-Cyclen dispute

NEW YORK &#8212 Watson Pharmaceuticals Inc. said Wednesday it settled a patent lawsuit brought by a unit of Johnson & Johnson over a generic version of the birth control drug Ortho Tri-Cyclen Lo.

Comment?

Related Topix: Food, J and J Snack Foods, Medicine, Ortho Tri-Cyclen, Estrogen/Progestin (generic), Medication, Biotech, Pharmaceuticals, Healthcare Industry, Johnson & Johnson, Johnson and Johnson, Johnson and Johnson Merck Consumer Pharmaceuticals

Tue Feb 07, 2012

Seeking Alpha

3 S&P 500 Companies Undervalued By EPS Trends Reporting Earnings Next Week

If you're interested in finding stocks that may be undervalued, here are some ideas to get started on your search.

Comment?

Related Topix: Financial Markets, Biotech, Medicine, Pharmaceuticals, Healthcare Industry, Marketing

Wall St. Cheat Sheet

Equity Analysis: Watson Pharma, Coinstar, HCA, FedEx, Express Scripts

Watson Pharmaceuticals Inc. : Leerink says day one of the Lidoderm patent trial produced no surprises, adding it continues to expect Watson Pharmaceuticals to prevail.

Comment?

Related Topix: Express Scripts, Financial Services, Computers, Coinstar, Biotech, Medicine, Pharmaceuticals, Healthcare Industry, Endo Pharmaceuticals Holdings, Endo Pharmaceuticals, Medco Health Solution, Insurance

Mon Feb 06, 2012

The Paramus Post

Watson Announces New Jersey-Based Global R&D Technology Center

Watson Pharmaceuticals, Inc. today announced plans to establish a Global R&D Technology Center in North Brunswick, New Jersey.

Comment?

Related Topix: New Jersey, Biotech, Medicine, Pharmaceuticals, Healthcare Industry, North Brunswick, NJ, Chris Christie, US Governors, Rutgers University, Parsippany, NJ

Fri Feb 03, 2012

Freshnews

Watson Provides Update on Generic LidodermA Application

PARSIPPANY, N.J., Feb. 3, 2012 /PRNewswire/ -- In response to investment community speculation following release of the transcript of a pre-trial conference call related to its Lidoderm patent challenge, Watson Pharmaceuticals, Inc.

Comment?

Related Topix: Healthcare Law, Law, Biotech, Medicine, Pharmaceuticals, Healthcare Industry, Food and Drug Administration

Mon Jan 30, 2012

Freshnews

Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2011 Earnings

Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the Company intends to release its fourth quarter 2011 financial results on Tuesday, February 14, 2012 prior to the open of the U.S. financial markets.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Pharmaceuticals

Stock Market Review

Watson in an Upbeat Mood - Analyst Blog

Watson Pharmaceuticals Inc. was recently buoyed by the news that the United States Court of Appeals has granted a stay of the preliminary injunction, which was preventing Watson Pharma and partner Amphastar Pharmaceuticals Inc.

Comment?

Related Topix: Biotech, Medicine, Pharmaceuticals, Healthcare Industry, Marketing, Angina, Health, Pain

BioSpace

Watson Pharmaceuticals, Inc. Announces New Jersey-Based Global R&D Technology Center

The Company has signed a lease for a 32,000-square-foot facility at the New Jersey Economic Development Authority's Technology Centre of The Company plans to immediately retrofit approximately 19,000 square feet of space for product development and analytical laboratories.

Comment?

Related Topix: Biotech, Medicine, Pharmaceuticals, Healthcare Industry

Business Journal

Generic for Watson Pharmaceuticals high blood pressure drug OK'd

Sales of hydrochlorothiazide capsules were about $204 million for the 12 months ending October 2011, according to the pharmaceutical information services and publishing company Wolters Kluwer.

Comment?

Related Topix: Biotech, Medicine, Pharmaceuticals, Hypertension, Health, Healthcare Industry, Hydrochlorothiazide (generic), Medication

Theflyonthewall.com

Lannett receives FDA approval for Hydrochlorothiazide Capsules, 12.5mg

Lannett Company announced it has received approval from the FDA of its Abbreviated New Drug Application for Hydrochlorothiazide Capsules, 12.5 mg.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Pharmaceuticals

Also on Topix